Sareum provided an update on operational activities and pipeline progress ahead of its Annual General Meeting (AGM) today. The Company made good progress in 2023 with its lead programme, SDC-1801, with a Phase 1a clinical trial underway in Melbourne, Australia.
SDC-1801: SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis. Sareum believes that dual TYK2 and JAK1 inhibition offers sign ....
